An Online Treatment Decision Aid for Men with Low-risk Prostate Cancer Eligible for Active Surveillance and Their Partners Increases the Uptake of Active Surveillance: The Navigate Randomised Controlled Trial
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.An online decision aid significantly increased active surveillance (AS) uptake for low-risk prostate cancer (LRPC) and improved decision-making preparedness compared to usual care. This supports using DAs to reduce treatment-related morbidity.
Area Of Science
- Oncology
- Decision Science
- Health Services Research
Background
- Curative treatment for low-risk prostate cancer (LRPC) offers no survival advantage over active surveillance (AS).
- Treatment choice for LRPC is a value-sensitive decision.
- A tailored decision aid (DA) for the Australian context is needed.
Purpose Of The Study
- To evaluate the impact of an online DA (Navigate) on AS uptake.
- To assess the effect of the DA on quality of life and decision-making in Australian men with LRPC.
Main Methods
- A parallel-group, prospective, randomised controlled trial.
- Recruited 302 men with LRPC, randomised 1:1 to an online DA (Navigate) or usual care.
- Primary outcome: self-reported AS uptake at 1 month; secondary outcomes: decision preparedness, decisional conflict, regret, satisfaction, quality of life.
Main Results
- Higher AS uptake in the Navigate group (90.6%) versus usual care (79.0%; p=0.008).
- Navigate participants reported greater decision-making preparedness (p<0.001).
- No significant baseline differences between groups; partners' outcomes not significantly different.
Conclusions
- Online DAs increase AS uptake and decision-making preparedness for LRPC.
- DAs can potentially reduce treatment-related morbidity.
- Further research is needed to integrate DAs like Navigate into standard care.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...